Molbio Diagnostics IPO Seeks Growth with ₹940 Crore Fundraising Plan

Molbio Diagnostics, a prominent player in the molecular diagnostics sector, is set to launch an initial public offering (IPO) aiming to raise a total of ₹940 crore. The company plans to secure ₹200 crore through a fresh issue of shares, which will be directed towards capital expenditures. Simultaneously, an offer for sale is expected to generate ₹740 crore, leading to a reduction in the promoter group's stake from 46.6% to 43%.

Global Reach and Revenue Growth

Founded in 2000, Molbio Diagnostics has established a significant global footprint with six manufacturing facilities across India. Serving over 90 countries, the company caters to a diverse clientele, including government health programs, diagnostic laboratories, hospitals, and international healthcare organizations. A substantial portion of its revenue stems from tuberculosis diagnostic test kits, which are integral to its product lineup.

The company's financial health has shown robust growth, with revenue from operations increasing by 31.5% annually to reach ₹1,445.7 crore between FY24 and FY26. During the same period, net profit surged by 40.2% to ₹164.1 crore, while EBITDA rose by 33.2% to ₹328.2 crore, resulting in an improved EBITDA margin of 22.6% in FY26.

Focus on Innovation and Strategic Partnerships

Molbio’s innovation is exemplified by its 'Truenat' platform, a portable diagnostics system designed to deliver accurate test results within an hour, particularly in resource-limited settings. The company offers molecular testing solutions for over 30 diseases through 43 diagnostic assays and has expanded its offerings to include radiology, digital pathology, and breast health screening solutions through subsidiaries and strategic alliances.

Government and international aid agencies constitute over four-fifths of Molbio's revenue, highlighting the company's strong ties with institutional clients. Notably, 74% of its revenue is derived from the sale of test kits, with tuberculosis diagnostics accounting for 70% of this segment.

Investment Considerations

The IPO positions Molbio Diagnostics as an attractive investment for those with a high-risk appetite, given the company's solid financial performance and strategic growth initiatives. The company is seeking a price-earnings (P/E) multiple of up to 57, which aligns it with other prominent healthcare diagnostics and medical device firms like Poly Medicure and Dr. Lal PathLabs, whose P/E ratios range from 54 to 81.

As Molbio continues to expand its reach and innovate within the diagnostics field, the IPO could potentially offer long-term growth opportunities for investors willing to navigate the inherent risks of the healthcare sector.